Please try another search
Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its products comprise Aggrastat (tirofiban hydrochloride), (an intravenous anti-platelet drug for patients with acute coronary syndrome; and Brinavess (vernakalant IV), a novel, atrial-preferential antiarrhythmic agent for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria. Correvio Pharma Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada. As of May 27, 2020, Correvio Pharma Corp. operates as a subsidiary of Mercury Pharma Group Limited.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review